Search

Displaying results 2871 - 2880 of 10000 in total
  1. Drug

    Gallium nitrate

    go.drugbank.com/drugs/DB05260
    ApprovedInvestigational

    [A260816] Gallium nitrate is reported to possess antiresorptive and hypocalcemic effects on bone. … [L47726] Apart from cancer-related hypercalcemia, gallium nitrate has been studied in arthritis, autoimmune disorders, and tumours.[A260830]

  2. Drug

    CX-717

    go.drugbank.com/drugs/DB05047
    IllicitInvestigational

    CX-717 is an ampakine compound previously investigated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) and Alzheimer's disease.

  3. Drug

    Benzylfentanyl

    go.drugbank.com/drugs/DB09182
    ExperimentalIllicit

    Benzylfentanyl (R-4129) is a fentanyl analog opioid that was on the list of Schedule I drugs in America in 1985 due to its structural similarity to fentanyl. … Benzylfentanyl has a Ki of 213nM at the mu opioid receptor, binding around 200x less strongly than fentanyl itself.

  4. Drug

    Belumosudil

    go.drugbank.com/drugs/DB16703
    ApprovedInvestigational

    [L34754] In July 2022, Belumosudil was approved by Health Canada under the brand name RHOLISTIQ to treat the same condition in adult and pediatric patients 12 years or older.[L42925] … [L34749] In the treatment of GVHD, a condition in which donor T-cells begin to attack recipient tissues following allogeneic hematopoeitic stem cell transplantation (HSCT), belumosudil helps to resolve

  5. Drug

    Droxicam

    go.drugbank.com/drugs/DB09215
    ApprovedWithdrawn

    Droxicam is an oxicam non-steroidal anti-inflammatory drug and a prodrug of [DB00554]. … It is used to reduce pain and inflammation in musculoskeletal disorders such as rheumatoid arthritis and osteoarthritis.

  6. Drug

    Dronedarone

    go.drugbank.com/drugs/DB04855
    ApprovedInvestigational

    [T28] Commonly marketed as Multaq®, dronedarone was approved by the FDA in July 2009 and Health Canada in August 2009. … Atrial fibrillation is a common sustained arrhythmia where the treatment primarily focuses on stroke prevention and symptom management.

    Synonyms: N-(2-butyl-3-(4-(3-(dibutylamino)propoxy)benzoyl)-5-benzofuranyl)-methanesulfonamide, N-(2-butyl-3-(p-(3-(dibutylamino)propoxy)benzoyl)-5-benzofuranyl)methanesulfonamide
  7. Drug

    Talazoparib

    go.drugbank.com/drugs/DB11760
    ApprovedInvestigational

    [L47236] Developed by Pfizer, talazoparib was first approved by the FDA in October 2018 [A260346] and by the EMA in June 2019.[L47296] It was approved by Health Canada in September 2020. … [L47301] Talazoparib is currently used in the treatment of BRCA-mutated breast cancer and HRR-mutated prostate cancer.[L47236, L47301, L47306]

  8. Drug

    Sebelipase alfa

    go.drugbank.com/drugs/DB11563
    ApprovedInvestigational

    This lipid accumulation can lead to end-organ damage in the form of liver dysfunction or malabsorption secondary to intestinal dysfunction. … The lysosomal acid lipase (LAL) enzyme is found in lysosomes and is primarily responsible for the metabolism of lipids, and its absence or deficiency results in the accumulation of lipids in various organs

  9. Drug

    Quizartinib

    go.drugbank.com/drugs/DB12874
    ApprovedInvestigational

    with other targets in mind. … cytarabine consolidation, followed by a maintenance monotherapy resulted in a 22% reduction in the risk of death.

    Synonyms: N-(5-(1,1-Dimethylethyl)isoxazol-3-yl)-N'-(4-(7-(2-(morpholin-4-yl)ethoxy)imidazo(2,1-b)benzothiazol-2-yl)phenyl)urea
  10. Drug

    Leniolisib

    go.drugbank.com/drugs/DB16217
    ApprovedInvestigational

    [L45753] Investigations for using leniolisib in primary Sjögren’s syndrome are ongoing.[A258468] … The FDA approved leniolisib on March 24, 2023, making it the first treatment for activated phosphoinositide 3-kinase delta syndrome (APDS).